πŸ‡ΊπŸ‡Έ FDA
Patent

US 9676869

Conjugated anti-CD38 antibodies

granted A61KA61K2039/505A61K47/6871

Quick answer

US patent 9676869 (Conjugated anti-CD38 antibodies) held by Takeda Pharmaceutical Company Limited expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K47/6871, A61P, A61P1/00